about
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansSimultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelThe use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.Methods for predicting in vivo pharmacokinetics using data from in vitro assays.Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.Modelling atypical CYP3A4 kinetics: principles and pragmatism.Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions.PBPK models for the prediction of in vivo performance of oral dosage forms.Understanding the transport properties of metabolites: case studies and considerations for drug development.In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages.Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytesIC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications.Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.Kinetic characterization of rat hepatic uptake of 16 actively transported drugs.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
P50
Q27022933-C7713156-2D97-43B5-85C3-D49A09B6B732Q30511951-619BEAAA-7C36-438A-B9F3-83A7EDD5F974Q30670381-64A75796-8DBF-4183-ABF1-B36F5189FEECQ30776360-9C84EB8C-5910-4E33-99F8-24A3FC71E053Q31012256-AEBF14BB-EB90-4FB1-8880-B7ECA2B11D1BQ31061538-D200CE91-6164-43D2-9957-B350DA0D9E91Q33328165-43382E10-D76A-4BAB-8D1D-136B91F7B7BCQ33373620-DF79084A-A167-464C-8C5A-0207E41B99D2Q33383352-15F364EA-5AD1-4CF7-B3A4-F2CFE443CD81Q33549603-78E61508-3A36-4318-946F-19AD58555A6EQ33815038-3CB5AF01-D3E8-4E1C-AB8A-EB895923C153Q33965749-97658488-8C9D-4517-B0E0-6EA675F02F2BQ34161651-4AB24A32-0C7B-47AC-860B-2233344C6EC0Q34476096-8BA6E8D5-2F09-4B35-BCB6-E038EDCA8500Q35620660-12AF7AED-35DE-476E-9666-CED67565B70DQ35974399-FABAB02E-19DE-477D-8B28-49A2625958E8Q36990018-BA9958FE-96F3-4CA6-85FA-71BABDF6439CQ37294102-AD856EDB-8DA5-4685-84E7-423E92D8BCD2Q37704154-0205C3CF-55A4-4375-868B-1DB20D58AC90Q38141441-400D32B6-6D18-45B2-B49C-B4A3C892E29AQ38172011-E98F0650-845B-48C1-A8C1-6C6F06EDED6EQ38714210-73DB6305-810F-4C30-B819-B00CE30A2D0AQ40074903-1991CA04-30A4-4293-B462-8FBDEB01567AQ41759104-79433BE1-504F-4157-AD3A-AD1350180E74Q42282480-3339A683-CECA-4C6E-886D-418B43D4ABCBQ43129481-3A58EB67-2AE2-48A1-AE83-C204E7D02C58Q43767845-858A6A34-0375-4F3B-ACB0-57D4012F7831Q43965937-A7B22016-E49C-419A-BB1D-C434B95342A6Q44217916-1FA5C21A-20C9-4EC6-AC73-EF8FACEAA70CQ44550560-A66A1402-7258-4A3F-B13A-1809E8810457Q44550572-EB443656-E3CB-4088-9C45-D8307E10700EQ44811098-DE6D9179-D702-49B1-9BD5-D2FF38216A71Q44837867-42C5047C-FB62-4F63-8930-7D287A04490DQ45040921-88A65A29-02F9-4D83-A488-218BE2737751Q45753948-EF51F232-644A-4E18-A5E7-29380BE12D95Q45851771-F68F4E15-5682-4A02-8AC7-BD5FEF9A7B25Q45939780-1244BF8E-12A0-4D10-BC9C-5642400AB449Q46135472-7BB1D312-6107-4AA8-A273-27F1F5B2875FQ46137927-48917662-074F-4532-8EA8-CB3B6D5AD66DQ46591069-AEA2A1DB-0DA7-4479-9CE2-6F891A694D89
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Aleksandra Galetin
@ast
Aleksandra Galetin
@en
Aleksandra Galetin
@es
Aleksandra Galetin
@nl
type
label
Aleksandra Galetin
@ast
Aleksandra Galetin
@en
Aleksandra Galetin
@es
Aleksandra Galetin
@nl
prefLabel
Aleksandra Galetin
@ast
Aleksandra Galetin
@en
Aleksandra Galetin
@es
Aleksandra Galetin
@nl
P106
P1153
6602510668
P21
P31
P496
0000-0002-3933-5217